Combination therapy shows promising results in newly diagnosed multiple myeloma patients
An overall response of 100% with isatuximab plus carfilzomib, lenalidomide and dexamethasone and a progression free survival rate for the first 50 patients of 79.6% and 75.5% after 12 and 24 months are good news for patients with newly diagnosed multiple myeloma.